Posted 18 January 2013
On 16 August 2012, the ASA held that the claims made by the respondent in its advertising was unsubstantiated and in breach and in breach of Clause 4.1 of Section II: “… DONA ® has been clinically proven to not only aid in the reduction of pain, inflammation and swelling of affected joints in OA, but also to improve mobility and prevent further progression of OA”. Nycomed-Dona submitted new substantiation in terms of Clause 4.1.7 of Section II. The ASA accepted the new evidence and the previous ruling was therefore overturned and Nycomed-Dona may continue using the claim.
… Read the rest